Bernadette J Huho et al | 18 Apr 2023 | Malaria Journal
Benefits of ACT in suppressing transmission are more likely to be evident where transmission is already low or effective vector control is widely implemented.
Jessica Cohen et al | 23 Mar 2024 | Malaria Journal
Overall, adherence to subsidized ACT purchased over-the-counter was found to be moderate. Further, a non-trivial fraction of those who complete treatment are taking the full course too quickly.
Jessica Cohen, Pascaline Dupas & Simone Schaner | 15 Mar 2024 | Stanford
In response to parasite resistance to older malaria medicines, the global health community is considering making new, more effective malaria treatments called Artemisinin Combination Therapies (ACTs) available over-the-counter at heavily subsidized rates throughout Africa.
Paul Newton et al | 13 Dec 2023 | Malaria Journal
Criminals are producing diverse harmful anti-malarial counterfeits with important public health consequences. The presence of artesunate monotherapy, substandard and/or degraded and counterfeit medicines containing sub-therapeutic amounts of unexpected anti-malarials will engender drug resistance.
Tanya Shewchuk et al | 31 Oct 2023 | Malaria Journal
ACTwatch is a unique multi-country research project that threads together anti-malarial supply and consumer behaviour to provide an evidence base to policy makers that can help determine where interventions may positively impact access to and use of quality-assured ACT and RDTs. Because of its ability to detect change over time, it is well suited to monitor the effects of policy or intervention developments in a country.
Mary Hamel et al. | 31 Oct 2023 | American Journal of Tropical Medicine and Hygiene
We report and explore changes in child mortality in a rural area of Kenya during 2003-2009, when major public health interventions were scaled-up. Mortality ratios and rates were calculated by using the Kenya Medical Research Institute/Centers for Disease Control and Prevention Demographic Surveillance System.
Gavin Yamey & Marco Schäferhoff | 05 Apr 2024 | Evidence to Policy Initiative (E2Pi)
The Affordable Medicines Facility-malaria (AMFm), a donor-funded global price subsidy, has been proposed as a strategy to increase ACT use in malaria-endemic countries. Given that donor-supported ACT subsidy schemes are costly, it is crucial to ensure that they have their intended impact. In this Policy Brief, E2Pi reviews the available literature evaluating whether previous private sector ACT subsidy schemes have worked or not. The brief also discusses the implications of these schemes for the initial two-year AMF m pilot phase (Phase 1).
Billy E Ngasala et al | 16 Mar 2024 | Malaria Journal
Provision of AL by CHWs for unsupervised malaria treatment at home was highly effective, which provides evidence base for scaling-up implementation of HMM with AL in Tanzania.
Michael Nambozi et al | 28 Feb 2024 | Malaria Journal
DHA/PQP was as efficacious, safe and well tolerated in treatment of uncomplicated malaria as AL, though in the latter group more new infections during the follow up were observed. DHA/PQP seems a potential candidate to be used as an alternative first-line or rescue treatment in Zambia.
Elizabeth Juma & Dejan Zurovac | 07 Jan 2024 | Malaria Journal
Overall, malaria testing rates were low and, despite different
age-specific recommendations, only moderate differences in testing rates
between the two age groups were observed at facilities with available
diagnostics.